חוב לטווח קצר להון עצמי Artelo (ARTL)

Artelo Biosciences focuses its business on developing cannabinoid receptor modulators to treat chronic pain and cancer-related anorexia. This chart illustrates the asset's price action, while the individual debt-to-equity ratio stands at 0.01. Growth for Artelo Biosciences is driven by successful Phase II trials of the ART27.13 drug, the development of neuropathy therapies, and the strengthening of intellectual property rights within the lipid sector.

Due to minimal geopolitical risks in the biopharmaceutical sector, the stability of Artelo Biosciences (ARTL) allows for an assessment of the balance between financial prudence and the efficient use of debt with maturities exceeding one year to cover peak loads via changes in the short-term debt-to-equity ratio on GURU.Markets, which determines the company's ability to scale research without risking a loss of liquidity.